-+ 0.00%
-+ 0.00%
-+ 0.00%

Cellectar Biosciences To Present Three Posters For Its Radiopharmaceutical Candidate At American Society Of Hematology Annual Meeting

Benzinga·11/04/2026 14:08:59
Listen to the news

Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of cancer therapies, today announced that three posters highlighting compelling data and clinical progress for its lead radiopharmaceutical candidate, iopofosine I 131 in Waldenström macroglobulinemia (WM), will be presented at the upcoming American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 12 – 15 in New Orleans, Louisiana.